Pomalidomide combinations in randomized trials are generating exciting data for relapsed/refractory multiple myeloma (MM). Here, Meletios Dimopoulos, MD, from the Kapodistrian University of Athens School of Medicine, Athens, Greece, provides insight into the ELOQUENT-3 (NCT02654132) and OPTIMISMM (NCT01734928) trials for patients who have failed proteosome inhibitor and immunomodulatory agent therapy, whilst also touching upon the future of treatment. Both of these trials compared different combinations and doses of pomalidomide and dexamethasone with either elotuzumab or bortezomib, resulting in great tolerability with few adverse events. This was recorded at the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden.
Randomized trials of pomalidomide combinations for MM
